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The B-cell receptor (BCR) is a key player of the adaptive immune system. It is a unique part
of immunoglobulin (Ig) molecules expressed on the surface of B cells. In case of many B-
cell lymphomas, the tumor cells express a tumor-specific and functionally active BCR, also
known as idiotype. Utilizing the idiotype as target for lymphoma therapy has emerged to
be demanding since the idiotype differs from patient to patient. Previous studies have
shown that shark-derived antibody domains (vNARs) isolated from a semi-synthetic
CDR3-randomized library allow for the rapid generation of anti-idiotype binders. In this
study, we evaluated the potential of generating patient-specific binders against the
idiotype of lymphomas. To this end, the BCRs of three different lymphoma cell lines
SUP-B8, Daudi, and IM-9 were identified, the variable domains were reformatted and the
resulting monoclonal antibodies produced. The SUP-B8 BCR served as antigen in
fluorescence-activated cell sorting (FACS)-based screening of the yeast-displayed
vNAR libraries which resulted after three rounds of screening in the enrichment of
antigen-binding vNARs. Five vNARs were expressed as Fc fusion proteins and
consequently analyzed for their binding to soluble antigen using biolayer interferometry
(BLI) revealing binding constants in the lower single-digit nanomolar range. These variants
showed specific binding to the parental SUP-B8 cell line confirming a similar folding of the
recombinantly expressed proteins compared with the native cell surface-presented BCR.
First initial experiments to utilize the generated vNAR-Fc variants for BCR-clustering to
induce apoptosis or ADCC/ADCP did not result in a significant decrease of cell viability.
Here, we report an alternative approach for a personalized B-cell lymphoma therapy
based on the construction of vNAR-Fc antibody-drug conjugates to enable specific killing
of malignant B cells, which may widen the therapeutic window for B-cell
lymphoma therapy.
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In recent years, monoclonal antibodies have emerged as
therapeutics with exceptional relevance for inflammatory and
infectious diseases and the treatment of cancer (1). The number
of antibodies in late-stage clinical trials has substantially
increased to over 50 in the year 2017. Furthermore, in this
year the number of novel antibody therapeutics that were
approved in either United States or the European Union
reached double-digit numbers for the first time (2). Being
approved in 1997, the monoclonal antibody (mAb) Rituximab
was the first FDA approved mAB specifically for cancer
treatment and was for a long time the most sold biologic drug
in clinical oncology. Rituximab is active in a diversity of human
lymphomas and chronic lymphocytic leukemia (3). Rituximab is
a chimeric mAB targeting the CD20 antigen present on both
healthy B cells as well as on most B-cell lymphomas.
Today 5% of all newly diagnosed malignancies are
lymphoma-related (4). More than 90% of adult lymphomas are
mature B-cell non-Hodgkin lymphomas (B-NHL), with a large
variety of histological subtypes (5). Besides Rituximab, a plethora
of different small molecules and mAbs have been developed that
either target different CD20 epitopes (for instance ofatumumab
and obinutuzumab) or other B-cell specific antigens as CD19,
CD22, and CD30 (6–10). For B-cell targeting with increased
efficacy, the effect of antibody-drug conjugates (ADCs) has been
analyzed in clinical trials (11). The mentioned different antibody
therapies share the characteristic of targeting B cells in a non-
specific manner. CD20 and other potential surface markers are
present on B cells regardless of the targeted cell being malignant
or not. Thus, all of the approved therapeutics can lead to severe
side effects (12). As a consequence, the specific targeting of tumor
cells might emerge as beneficial for lymphoma therapies (13, 14).
Most B-cell lymphomas express a cell surface immunoglobulin
molecule referred to as B-cell receptor (BCR).The BCR consists of a
membrane-anchored immunoglobulin (Ig) associated with
transmembrane proteins. The extracellular region of the BCR is
anantibodynormally servingas recognitionsite for foreignantigens
(15). It has a crucial role in signaling after first encounter of a B cell
with its cognate antigen. Here, the BCR mediates antigen
internalization and the subsequent presentation of peptides to T-
helper cells. This results in triggering of cell proliferation,
differentiation and the generation of memory B cells and
antibody-secreting B cells (16).
In general, B-cell lymphomas develop from clonal
populations of precursor B cells in different stages of B-cellAbbreviations: ADC, antibody-drug conjugate; ADCC, antibody-dependent
cellular cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; Aga2p,
a-agglutinin II subunit; APC, antigen-presenting cell; BCR, B-cell receptor; BLI,
biolayer interferometry; BSA, bovine serum albumin; ELISA, enzyme-linked
immunosorbent assay; CDR, complementarity-determining region; Fab,
antigen-binding fragment; FACS, fluorescence-activated cell sorting; GPI,
glycosylphosphatidyl-inositol; Id, idiotype; Ig, immunoglobulin; KB, kinetics
buffer; mAb, monoclonal antibodies; MMAE, monomethyl auristatin E; PBMCs,
peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PCR,
polymerase chain reaction.
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lymphoma patient since variable regions of BCRs are generated
by random rearrangement of germ line immunoglobulin genes
(17). During malignant transformation of a B cell, each cell of the
formed clonal population expresses the same unique BCR, the
so-called idiotype (Id).
Specific binding can not only be utilized for specific cellular
targeting but also for induction of anergy and clonal deletion of
lymphoma cells. This occurs when B-cells perceive a BCR
stimulus in the absence of T-cell help (18), Toll-like receptor
binding or cytokine signals from accessory cells (19).
Consequently, the BCR might act as a tumor-specific and
functionally active cell surface marker able to trigger apoptosis.
Previous studies have shown the general applicability of
mAbs directed against the patient-specific Ids in lymphoma
studies (20). Although these studies have confirmed the safe
administration and positive immunological effects in-vivo, the
strategy of Id-targeting has not emerged as a widespread therapy
for lymphomas until now. The most important limiting factor
was the requirement to generate tailor-made mAbs for every
single patient. Since the application of classical hybridoma
technology (21) for producing individualized mAbs was not
feasible in a cost-effective process, this strategy was not further
investigated extensively in the following years. The group of Ron
Levy, one of the pioneers of anti-Id mAbs for lymphoma
treatment (20, 22), brought the issue of anti Id-mAbs back on
the agenda: They published a new concept for patient-
specific lymphoma targeting based on anti-Id peptides in
2016 (23).
The respective peptides specifically recognizing the BCR were
identified by screening a phage-display library (24), chemically
synthesized, and then coupled chemically to the amino terminus of
a premade IgG Fc protein. They clearly demonstrated the specific
recognition of tumor cells in vitro, confirmed the triggering of
tumor cell apoptosis and phagocytosis by macrophages, and
effectively cleared human lymphoma cells in a murine xenograft
model. However, utilizing peptides for specific BCR-binding might
have some drawbacks, for example a short half-life in-vivo and
their significant unspecific binding after administration that might
occur. To evaluate alternatives to this strategy, we decided to use
shark-derived antibody fragments for the generation of anti-
Id binders.
Compared to conventional antibodies from mammals,
cartilaginous fish like sharks have a unique form of heavy chain-
only antibodies, termed immunoglobulin new antigen receptor
(IgNAR) (25). Molecules of this type are devoid of any light chain
but possess heavy chains comprised of five constant domains
followed by the variable domain (vNAR) that is exclusively
responsible for antigen binding. Since vNARs lack the hydrophobic
VH–VL interface of a conventional antibody, they are reported to
have an increased water solubility (26, 27). Furthermore, vNARs
only possess two (CDR1 and CDR3) CDR loops leading to the fact
that vNARs, with a size of 11 to 12 kDa, are the smallest antigen-
binding antibody-like domain in the animal kingdom (28). Of note,
the elongated CDR3 loop primarily mediating antigen-binding is
at least partly able to compensate for the lack of the CDR2 loop.November 2020 | Volume 11 | Article 560244
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CDR3 loop, are able to interact with hidden, cleft-like epitopes
not able to be recognized by conventional antibodies. Besides the
isolation of vNARs directed against therapeutically relevant target
proteins as TNFa (29), the malaria-related AMA protein (30) or
EpCAM (31), it has been shown that vNARs can be engineered
towards pH-sensitive antigen-binding (32) for application in
biotechnological applications. Recently, it was shown that screening
of semi-synthetic and CDR3-randomized vNAR libraries in
combination with yeast surface display allows for the fast and
convenient identification of anti-idiotypic vNAR domains directed
against the paratope of mAbs (33). The resulting anti-idiotypic
vNAR variants were not cross-reactive towards unrelated antibodies
and retained their excellent target recognition in the presence of
human and murine serum.
Based on these experimental experiences, we investigated in
this study whether this strategy can also be applied to the
isolation of anti-idiotype vNARs specifically recognizing the
BCR of lymphoma cell lines and finally inducing cell death
(Figure 1). Here we show that yeast library screening for vNARs
directed against soluble BCR SUP-B8 lymphoma cells results in
anti-idiotype vNARs showing specific receptor binding. Since we
could not observe the induction of apoptosis via clustering of
BCR molecules in first initial experiments, we developed an
alternative approach by generating vNAR antibody-drug
conjugates that induced specific killing in lymphoma cells at
low nanomolar concentrations.Frontiers in Immunology | www.frontiersin.org 3MATERIALS AND METHODS
Experiments with human effector cells were approved by the
Ethics Committees of the participating institutions in accordance
with the Declaration of Helsinki.
Cell Lines, RNA Isolation, and cDNA
Synthesis
Three immunoglobulin expressing lymphoma cell lines Daudi,
IM-9, and SUP-B8 (obtained from the group of Prof. Ron Levy)
were used for idiotype cloning. Daudi and IM-9 cells were grown
in RPMI-1640 medium with 10% FBS and 2 mM glutamine.
SUP-B8 cells were treated the same way except using 15% FBS
for cultivation. Extraction of total RNA from 1 × 107 human
lymphoma cells was carried out after cell homogenization with
QIAshredder (Qiagen) using the commercially available kit
RNeasy Minikit (Qiagen) according to the supplier's protocol.
Subsequently, cDNA-synthesis was carried out using 50 µl RNA
extract, 10 µl random hexamer primers (50 ng/µl), 10 µl 50 µM
dNTPs, 30 µl H2O, 40 µl 25 mM MgCl2, 20 µl 10× RT-buffer,
20 µl 0.1 M DTT, 10 µl RNase OUT, and 10 µl SuperScript III
reverse transcriptase (all components acquired from SuperScript
III First-Strand Kit, Thermo Fisher Scientific). Incubation for
5 min at 25°C was followed by incubation for 60 min at 50°C
and an inactivation step at 85°C for 5 min. Subsequently, 1 µl
RNAaseH was added and the reaction was incubated for 20 min
at 37°C. The synthesized cDNA was stored at −20°C.FIGURE 1 | Concept overview. RNA of B cells presenting a tumor-specific B-cell receptor is extracted followed by cDNA synthesis. After amplification of genes
coding for variable domains, soluble BCR molecules are expressed in mammalian cells. A semi-synthetic shark-derived vNAR yeast library is screened to identify
anti-idiotype binders. After expression as vNAR-Fc molecules, these candidates are analyzed for their specific cellular binding and their potential to induce cell death.November 2020 | Volume 11 | Article 560244
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Variable antibody regions were amplified from cDNA in two
different PCR reactions using Taq or Q5 Polymerase (NEB) in a
reaction volume of 100 µl. For each cell line and chain, the
reactions were prepared using 1 to 2 µl cDNA. Amplification of
VH and VL genes was carried out using the primers listed in Tab.
S1. A detailed overview about the amplification strategy can be
found in a publication byMaleshko et al. (34). For all reactions the
following conditions were set: 95°C for 30 s, 30 cycles of 20 s at
95°C, 30 s at 57°C, and 30 s at 68°C, followed by 68°C for 5 min.
PCR products were purified via Wizard® SV Gel and PCR
Clean-up System (Promega). Afterwards PCR products were
sent for sequencing by the company Seqlab. For cloning of
B-cell receptors of all used cell line VH genes were amplified
using primers introducing restriction sites for BamHI and
ApaI (Daudi_HC_BamHI_up/IM9_HC_BamHI_up/SUPB8_
HC_BamHI_up and Daudi_HC_ApaI_lo/IM9_HC_ApaI_lo/
SUPB8_HC_ApaI_lo). For light chain cloning of Daudi and IM-
9 cell lines VL genes and the Ck domain were amplified separately
utilizing theprimersDaudi_LC_BamHI_up/IM9_LC_BamHI_up
and Daudi_LC_SOE_LO/IM9_LC_SOE_LO for VL genes on
the one hand and Daudi_LC_SOE_UP/IM9_LC_SOE_UP with
LC_kappa_NotI_lo for Ck on the other hand. For the latter
reaction a vector bearing the coding sequence for Matuzumab
kappa light chain served as template. Afterwards fusion PCR was
performed using the primer pair IM9_LC_up/ Daudi_LC_up
and LC_kappa_NotI_lo. 20 ng of each domain was amplified
using Taq polymerase for 15 cycles without addition of
oligonucleotides with an elongation time of 50 s. Subsequently,
15 PCR cycles were performed after addition of oligonucleotides.
Afterwards the products were purified via Wizard® SV Gel and
PCR Clean-up System. Light chain of SUPB8 was constructed in
a similar way: After separate amplification of VL genes using
the primers SUPB8_LC_BamHI_up and SUPB8_LC_SOE_lo
and the Cl domain using the oligonucleotides SUPB8_LC_
SOE_up and SUPB8_Lambda_NotI_lo. For the latter reaction
the vector pYD_lambda_constant with the coding sequence for
lambda light chain served as template. Subsequent fusion PCR
and purification was performed according to the generation of
Daudi and IM9 light chains. Restriction of PCR products and
vectors pTT5-hu425H/pTT5-hu425L (NRC Biotechnology
Research Institute) with the respective restriction enzymes was
followed by ligation and transformation into Escherichia coli
strain DH5a. After incubation overnight plasmids were isolated
using the PureYield™ Plasmid Miniprep System (Promega)
followed by sequence verification. After that Expi293F™ cells
were transiently transfected using polyethyleneimine (Polysciences)
according to the instructions of the manufacturer (Thermo Fisher
Scientific). After 5 days the respective culture supernatants were
harvested, sterile-filtered (0.22 mm Filtropur S 0.2, Sarstedt) and
purified using HiTrap Protein A HP columns (GE Healthcare) in
combination with an ÄKTA purification system (GE Healthcare).
This was followed by buffer exchange via dialysis against PBS
using amembrane with aMWCO~ 14 kDa. The purified proteins
were stored at −80°C.Frontiers in Immunology | www.frontiersin.org 4Yeast Strains, Media, and Reagents
Saccharomyces cerevisiae strain EBY100was utilized for yeast surface
display (35). YPDmediumwas composed of 20 g/L dextrose, 20 g/L
tryptone, and 10 g/L yeast extract. SD-CAA medium was prepared
using 8.6 g/L NaH2PO4 × H2O, 5.4 g/L Na2HPO4, 1.7 g/L yeast
nitrogen base without amino acids, 5 g/L ammonium sulphate, 5 g/L
bacto casamino acids, and 20 g/L dextrose. SG-CAA medium was
prepared the same way except for the substitution of glucose sugar
with galactose. Phosphate-buffered saline (PBS) was prepared with
8.1 g/LNaCl, 1.13 g/LNa2HPO4, 0.75 g/LKCl, and0.27 g/LKH2PO4.
Yeast Library Construction
The generation of semi-synthetic vNAR yeast display libraries
was extensively described by Grzeschik et al. (36). Briefly, the
PCR-amplified vNAR products from three non-immunized
bamboo sharks were used as template for a consecutive three-
step PCR. At first a cysteine in CDR1 was mutated to tyrosine to
prevent the non-specific generation of disulfide bridges. In the
second PCR, randomization of either 12, 14, 16 or 18 amino
acids in the CDR3 was performed using a codon-based
trinucleotide mixture (EllaBiotech) that consisted of each
amino acid-encoding trimer except the one for cysteine.
Performing the third PCR allowed for attachment of homologous
sequences for gap repair cloning in yeast with the linearized pCT
vector (35). PCR products were purified using the Wizard® SV Gel
and PCR Clean-up System (Promega) according to the
manufacturer's protocol. The pCT plasmid used for gap repair
cloning and surface presentation of vNAR variants was digested
with the restriction enzymesNheI-HF and BamHI-HF and purified
using the Wizard® SV Gel and PCR Clean-up System (Promega).
Library generation in S. cerevisiae EBY100 cells was performed as
described by Benatuil and colleagues (37). Each electroporation
reaction consisted of 1.5 mg digested pCT plasmid and 4.5 mg insert.
Altogether 10 transformation reactions per library were performed.
Dilution plating was performed in order to determine the library
size after three days.
Yeast Library Screening
Yeast cells were cultured as described (38). In short, transformed
yeast cultures were incubated over night at 30°C in SD-CAA
medium. Cells were collected via centrifugation, resuspended in
SG-CAA medium at OD600 = 0.7 and cultivated overnight at
20°C. For staining, cells were harvested and resuspended in BPBS
(PBS + 0.1 % BSA). In general, 107 cells were incubated in a
volume of 20 µl and upscaled if necessary. For each staining a
negative control in absence of target protein was included. For
the first two sorting rounds cells were incubated with 1 µM SUP-
B8 BCR and anti-c-myc-Biotin antibody (Miltenyi Biotec; 1:50
diluted) for 30 min on ice. After washing with BPBS, antigen
binding was detected by application of anti-Human IgG Fc-PE
conjugate (Affymetrix eBioscience; diluted 1:75) or Goat F(ab′)2
Anti-Human Lambda-PE (Southern Biotech; diluted 1:80) in
combination with Streptavidin conjugated to APC or PE
(Affymetrix eBioscience; diluted 1:75). Afterwards, cells were
washed once with BPBS, resuspended in PBS and analyzed with aNovember 2020 | Volume 11 | Article 560244
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manufacturer and analyzed via BD FACS™ Sortware v1.0.
Setting of sort gates typically allowed 0.1% to 0.3% false-
positive cells as judged by control staining in the absence of
antigen. After sorting cells were subsequently transferred to SD-
CAA medium for further incubation at 30°C for 2 days. Further
sorting rounds were performed with at least a 10-fold excess of
cells sorted out in the previous round to guarantee a sufficient
coverage of the enriched populations. After enrichment of
antigen-binding variants yeast cells plasmid DNA from
antigen-binding populations was isolated using Zymoprep
Yeast Plasmid Miniprep Kit (Zymo Research) and transformed
into DH5a competent E. coli cells. After incubation overnight
plasmids were isolated and sent out for sequencing utilizing
pCT_seq_lo and pCT_seq_up oligonucleotides.
Expression of Selected vNAR-Fc Variants
For expression of soluble vNAR molecules, genes were
reformatted via fusion to human IgG1 Fc region encoded in
the mammalian expression vector pEXPR-IBA42 (CosmoBio).
For ligation NheI and ApaI sites and parts of the IgG1 hinge
region were introduced via PCR. After restriction of entry
plasmids and vNAR genes with the respective restriction
enzymes and ligation and transformation of E. coli, sequencing
of constructs was performed followed by transient transfection of
Expi293FTM cells using polyethyleneimine (Polysciences)
according to the instructions of the manufacturer (Thermo
Fisher Scientific). After 5 days, culture supernatants were
harvested, sterile-filtered (0.22 mm Filtropur S 0.2, Sarstedt)
and purified using Protein A spin columns. Buffer exchange
was performed via dialysis against PBS using a membrane with a
MWCO ~ 14 kDa.
Binding Kinetics
For evaluation of binding kinetics parameters measurements
were carried out on Octet RED96 system (FortéBio) at 30°C
and 1000 rpm agitation in 200 µl. SUP-B8 BCR molecules were
loaded on Anti-Human Fab-CH1 2nd Generation at 2 µg/mL in
KB for 80 s. After that tips were transferred to kinetics buffer
(KB; PBS, 0.1% Tween 20 and 1% BSA) for 60 s for sensor
rinsing. Subsequently, association of varying concentrations
from 2.4 to 200 nM of different vNAR-Fc variants were
measured for 300 s followed by dissociation for 300 s in KB. In
each experiment, a negative control was performed by incubating
the captured BCR molecules with unrelated antigen or
incubating tips loaded with unrelated antigen with soluble
vNAR-Fc. Data fitting and analysis was conducted with
FortéBio data analysis software 9.1 with a 1:1 Langmuir
binding model after Savitzky–Golay filtering.
Cellular Binding
Prior to analysis proteins were biotinylated using EZ-Link™
Sulfo-NHS-LC-Biotin (ThermoFisher) according to the
instructions of the manufacturer. In scope of analyzing cellular
binding, cells were sedimented and washed three times with 1%
BPBS followed by incubation with the respective biotinylated
vNAR-Fc constructs (250, 50 or 10 nM vNAR-Fc in 1% BPBS)Frontiers in Immunology | www.frontiersin.org 5for 1 h. In the next step cells were washed and incubated with
fluorescently labeled Streptavidin-APC (diluted 1:75) for 20 min
and washed once again. In the end, cells were analyzed using a
BD Influx flow cytometry device.
Generation of vNAR Antibody-Drug
Conjugates
vNAR antibody-drug conjugates were generated upon enzymatic
ligation of the antimitotic agent Monomethyl Auristatin E
(MMAE) to the Fc fragment. Therefore, a genetically
engineered C-terminal LPETGG extension was modified by an
activity-optimized sortase variant (eSrtA) (39) from the Gram-
positive bacterial strain Staphylococcus aureus as described
elsewhere (40). Briefly, vNAR-Fc molecules were incubated in
the presence of 0.1 equivalents sortase A and 10 equivalents
GGG-vc-PABA-PEG3-MMAE in reaction buffer (150 mMNaCl,
50 mM TRIS, 10 mM CaCl2, pH 7.5 adjusted with HCl) for 1 h at
22°C. After protein modification, antibody-drug conjugates were
purified via protein A chromatography (GE Healthcare), buffer-
exchanged and concentrated to required concentrations
(Amicon® Ultra 15 mL, Millipore).
Cell-Based Assays
Isolation of Human Effector Cells
Human macrophages were generated by an adherence method
util izing monocyte-attachment medium (PromoCell ,
Heidelberg, DE). After an incubation for 24 h in serum-free X-
Vivo medium (Lonza, Basel, CH), M-CSF (PeproTech, Rocky
Hill, CA, USA) was added for macrophage generation. Human
MNC were isolated from peripheral blood of healthy volunteers,
as previously described (41) using Ficoll® (GE Healthcare,
Chicago USA).
Chromium Release Assays
ADCC was analyzed in [51Cr] release assays as described
previously (41). Briefly, effector cells, antibodies and medium
were added to round-bottom microtiter plates (Nunc, Rochester,
NY, USA) and the assay was started by adding target cells. After
3 h at 37°C, [51Cr] release from triplicate samples was measured.
The percentage of cellular cytotoxicity was calculated using the
formula: percentage of specific lysis = (experimental cpm − basal
cpm)/(maximal cpm − basal cpm) × 100; maximal [51Cr] release
was determined by adding 2 % v/v Triton-X-100 to target cells,
and basal release measured in the absence of sensitizing
antibodies and effector cells.
Phagocytosis Assays
ADCP was analyzed by high-throughput microscopy using the
IncuCyte® (Sartorius, Göttingen, DE) system. Human
macrophages served as effector cells in ADCP. For fluorescence
staining, 1 × 106 target cells were labeled with 0.5 µg/ml pHrodo
(ThermoFisher, Waltham, MA) for 1 h at room temperature.
Afterwards, target cells were washed two times in PBS and
diluted in either cell culture medium or 0.1 M glycine pH 3 as
positive control. The effector cell to target cell ratio (E:T ratio)
was 1:1 with 0.4 × 105 target cells as well as macrophages being
seeded per well. After adding antibodies at variousNovember 2020 | Volume 11 | Article 560244
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min and analyzed using IncuCyte® software tools.
Internalization Assays
vNAR-Fc fusion proteins were conjugated with pHAb amine
reactive dye according to manufacturer's recommended protocol
(Promega). Briefly, antibodies were reacted at lysine amino acids
with a 20 molar excess of amine reactive pHAb dye for 1 h.
Unbound dye was subsequently removed using a Zeba desalting
column (Thermo-Scientific). For internalization, B cells were
plated at the density of 2 × 104 vial cells per well and treated
overnight with pHAb conjugated vNAR-Fc antibodies at desired
concentrations. Plates were read on a fluorescent plate reader at
Ex/Em: 532 nm/560 nm.
Cell Proliferation Assays
Cytotoxic effect of vNAR constructs was evaluated by exposing
on-target SUP-B8 lymphoma B-cells or off-target cells to
different antibody concentrations. Cell viability was analyzed
72 h after addition of vNAR-Fc variants with the CellTiter 96®
AQueous One Solution Cell Proliferation Assay (Promega).
Briefly, 1 × 104 cells were seeded per well in a 96-well plate in
90 ml RPMI 1640 medium and treated with 10 ml vNAR-Fc
antibody to reach final concentrations of ~20 pM up to 1 µM.
After 72 h, 20 ml of the MTS solution were added per well and the
plates were incubated for 2 h under standard conditions. Finally,
the absorption of each well was measured at 490 nm in a Tecan
reader. Cell proliferation in reference wells with untreated cells
was set to 100 %.
Statistical Analysis
Statistical analysis was conducted using SigmaPlot 12.5 (Systat
Software, Inc.). Data are presented as mean ± standard error of
the mean (SEM) of at least three independent experiments.
Statistical significance was determined using a two-way
ANOVA test (Bonferroni t-test). p values <0.05 were
considered to be statistically significant.RESULTS
Identification and Generation of
Lymphoma Cell-Specific B-Cell Receptors
In order to identify lymphoma BCRs and provide them in soluble
form for library screening to obtain anti-idiotypic shark-derived
antibodies, three different lymphoma cell lines, namely Daudi,
IM-9, and SUP-B8 were used. First step was the generation of
cell-specific soluble BCR molecules for their later use as antigen
in a FACS-based selection process. Therefore, all cell lines were
cultured, followed by RNA extraction and subsequent cDNA
synthesis using random hexamer primers. Afterwards, the
synthesized cDNA served as template for amplification of VH
and VL genes using primers reported in a study by Maleshko
et al. (34) that elucidated a specially designed panel of primers for
the rapid amplification of variable regions of tumor
immunoglobulins (Tab. S1). The primers enabled the specificFrontiers in Immunology | www.frontiersin.org 6amplification of four possible immunoglobulin chain types IgM,
IgG, IgK, and IgL. After amplification of VH and VL domains
showing the correct fragment size (Figure S1A), purified PCR
products were sent for sequencing. Resulting sequences were
aligned to the published sequences of all three BCR variants (42,
43) and can be found in Figure S2. To use the 3 BCRs as antigen
in FACS based screening process in the next steps, the variable
domains were cloned on the Fc-scaffold of matuzumab (44). For
heavy chains, VH domains of matuzumab were exchanged
against the identified BCR VH domains. Due to the lack of
correct restriction sites for light chains, VL of Daudi and IM-9
were fused via PCR to CKappa domains and VL of SUP-B8 to
CLambda, respectively (Figure S1A).
After sequence verification, all constructs were cloned into
pTT5 vectors for expression in HEK 293F cells as described
elsewhere (45). Five days after transient transfection, cell cultures
were harvested and supernatants were purified using Protein-A
spin columns followed by dialysis against PBS. Analysis using
SDS-PAGE revealed the presence of all three BCR variants after
purification (Figure S1B). The BCRs of SUP-B8 and IM-9
showed the correct band pattern with heavy and light chain
bearing the correct size. However, the BCR variant of the Daudi
cell line showed a smearing band corresponding to the light
chain with a higher apparent molecular size than predicted. We
did not further investigate whether this difference in molecular
weight is due to Daudi VL domain glycosylation.
Yeast Library Screening
To investigate whether specific anti-idiotypic vNARs can be
obtained, the BCR of cell line SUP-B8 was utilized as antigen
in a FACS-based screening process using the semi-synthetic
vNAR yeast surface display library with randomized CDR3
loops in different lengths of 12 to 18 amino acids (32).
Consequently, the libraries were screened by FACS for binders
of recombinant SUP-B8 BCR protein. Target binding was
identified by indirect antigen fluorescence staining. vNAR
surface display level was analyzed simultaneously by labeling of
the C-terminally located c-Myc tag. Negative controls in absence
of antigen were carried out to evaluate the enrichment of binders
directed against the staining reagents considered in the gate
strategy. As depicted in Figure 2, we were able to enrich a SUP-
B8 BCR-positive yeast population within three consecutive
screening rounds by employing 1 µM antigen. Moreover, no
significant binding against secondary detection reagents
was observed.
Polyclonal anti-human IgG Fc-PE conjugate served as
detection reagent in each round. However, to prevent the
isolation of vNAR variants directed against this reagent, the
third sorting round was repeated using anti-human Lambda-PE,
recognizing the CLambda domain of SUP-B8 BCR (Figure S3). To
assess the specificity of the enriched binding populations, target
binding to IM-9 BCR and Cetuximab was analyzed and revealed
no significant binding (Figure S4).
A total of 15 yeast clones were selected and analyzed for their
target-specific binding to the SUP-B8 BCR using flow cytometry
(Figure S5). This resulted in 13 clones showing surface
presentation and specific BCR binding. Afterwards, sequencingNovember 2020 | Volume 11 | Article 560244
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determine the clone diversity still present in this populations.
Sequencing revealed the presence of 11 unique single clones
showing different CDR3 loop lengths of 12 to 16 amino acids
(Figure 3). No variant comprised of 18 amino acids in CDR3 was
enriched in the screening process.
Generation and Characterization of vNAR-
Fc Variants
For further characterization of the identified variants, eight
clones in total were chosen for reformatting based on reliable
sequence patterns and expressed as vNAR-Fc fusion proteins in
HEK 293F cells. After production and purification via protein A
affinity chromatography, the proteins were assessed by SDS-
PAGE, indicating for five clones bands with the expected
molecular weight of approximately 40 kDa as well as a high
purity (Figure S6). For characterization, binding kinetics of
binders resulting from screening campaigns were determined
via biolayer interferometry (BLI). This resulted for four clones in
binding affinities ranging from low single-digit nanomolar to low
double-digit nanomolar binding constants (Figure S7).
To assess the specificity of soluble vNAR-Fc variants, binding
to the BCRs of the unrelated cell line IM-9 was investigated. This
resulted in three variants S2, S4, and S9 that revealed mainly
specific binding whilst one variant (S7) showed significant
binding intensity to the unrelated BCR of cell line IM-9
(Figure S8). Within this study we aimed to demonstrate theFrontiers in Immunology | www.frontiersin.org 7feasibility of shark-derived vNAR antibody fragments selected
via yeast surface display for specific targeting of lymphoma cells.
Cellular binding to SUP-B8 cells was therefore analyzed to prove
the binding not only to the recombinantly expressed BCRs used
as antigen for screening procedure but also to the native surface-
presented BCR. Prior to analysis of cellular binding, surface
expression of BCRs was verified by staining cells with anti-
human lambda-PE or anti-human kappa-PE (Figure S9).
Selective cellular binding was analyzed by comparing the
binding to SUP-B8 cells with unspecific binding to BCR-
presenting Daudi and IM-9 cells. Binding experiments
indicated for 2 variants S2 and S9 a highly specific cellular
binding in an idiotypic manner (Figure 4A). Moreover,
experiments including primary B cells isolated from healthy
donors demonstrated the capability of the vNAR-Fc fusion
proteins to discriminate between the idiotype of the malignant
clone and a plethora of idiotypes expressed by healthy B cells of
an individual (Figure 4B). Of note, higher cell surface BCR
expression levels were observed on lymphoma B cells compared
with healthy B cells (Figure S10). Next, the ability of the vNAR-
based antibodies to cluster the idiotype of the lymphoma B cells
triggering BCR signal transduction was investigated. Antibody
treatment of lymphoma cell lines showed stimulation of
intracellular Syk phosphorylation, revealing specific mediation
of BCR signaling (Figure 4C).
Given the final goal of specific opsonizing lymphoma B cells,
the impact on receptor-mediated endocytosis was alsoFIGURE 2 | Shark-derived vNAR library screening against the BCR of cell line SUP-B8. Sorting gates, percentages of cells in the respective gate and target
concentrations are shown. Anti-Human Fc-PE served as detection reagent. 1 d after induction, yeast cells were labeled for parallel detection of antigen-binding and
surface presentation. In each round, cells in the sorting gate of the upper plots were isolated, grown and induced for the next round of selection. Outcome selected
rounds of screening were analyzed for specific enrichment (lower plots).November 2020 | Volume 11 | Article 560244
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levels upon specific engagement of the BCR (Figure S11).
vNAR-Mediated Tumor Cell Killing
Previous publications have shown the potential of BCR-binding
peptibodies bearing four binding valences to kill tumor cells in
vitro specifically by inducing cell apoptosis upon clustering of
surface BCRs (23). Initial experiments utilizing both vNAR-Fc
variants bearing only two binding valences showed no significant
cell killing effect on SUP-B8 cells (Figure S12A). Likewise, a
tetravalent version with four vNARs fused to the hinge region
mediated no cell killing. To analyze whether the novel molecules
trigger Fc-mediated effector functions, the capability of the
vNAR-Fc molecules to specifically mediate ADCC and ADCP
against malignant B-cells was investigated in 51chromium release
assays using increasing antibody concentrations and PBMCs or
macrophages, respectively, as effector cells (Figure S13). For
unknown reasons, no antibody-dependent cell-mediated
cytotoxicity or antibody-dependent cellular phagocytosis was
observed in these assays.
As an alternative approach, we intended to generate
antibody-drug conjugates for specific induction of cell killing
in SUP-B8 lymphoma B-cells. Therefore, sortase A-mediated
modification of our two most promising vNAR candidates S2
and S9 with monomethyl auristatin E (MMAE) was carried out
(Figure 5A).
To this end, on-target SUP-B8 cells as well as off-target Daudi
and IM-9 cells were treated with MMAE-conjugated vNAR-Fc
constructs at concentrations ranging from ~20 pM to 1 µM. S2
and S9 antibody-drug conjugates mediated specific cytotoxicityFrontiers in Immunology | www.frontiersin.org 8in target SUP-B8 cells with IC50 values in picomolar range (517
nM and 136 nM, respectively) and similar maximal level of
lymphoma cell lysis (Figures 5B, C). A cytotoxic effect was
observed in off-target Daudi and IM-9 cells at higher antibody
concentrations, showing, however, up to 345-fold higher EC50
values. Induction of specific cell death was additionally
confirmed in an Annexin V FACS assay (Figure 5F). Of note,
no significant killing effect could be detected on unrelated CHO
cells (Figure S12B). Cell death induced in off-target cell lines
might not be vNAR-related, as shown in experiments including
isotype controls as well as vNAR-devoid Fc-MMAE molecules
(Figures 5D, E). Differences observed between cell lines might be
derived from varying overall sensitivity to the drug.DISCUSSION
Using anti-idiotypic antibodies to target lymphoma B-cells has
aroused interest in the scientific community a long time ago. The
BCR might represent an ideal tumor-specific marker since this
functionally active molecule is unique for each B-cell clonal
population. Indeed, anti-idiotype antibody therapy in lymphoma
patients has been shown to be successful in small clinical studies
(46). The consequent need of developing a custom-tailored
therapy, however, delayed further progress.
In this study we demonstrate the suitability of semisynthetic
shark-derived vNAR antibodies for the development of a cost
and time-effective personalized therapy against B-cell
lymphoma. Thus, a yeast-displayed CDR3-randomized vNAR
library generated from non-immunized bamboo sharks wasFIGURE 3 | Sequence alignment of vNAR-Fc variants binding the BCR of lymphoma cell line SUP-B8. Sequencing was performed with clones derived from
population after three rounds of FACS screening using yeast display. CDR1 and CDR3 binding sites are depicted in grey and red.November 2020 | Volume 11 | Article 560244
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alyzed for their binding to the B-cell lymphoma cell lines SUP-B8, Daudi and IM-9 by flow cytometry. 2 ×
lack: only secondary reagent; red: 250 nM vNAR-Fc; blue: 50 nM vNAR-Fc; green: 10 nM vNAR-Fc (A).
a saturating 100-nM concentration of biotinylated vNAR-Fc antibodies followed by staining with
(S2); red: vNAR-Fc (S9) (B). Lymphoma B cells were incubated with vNAR-Fc antibodies at a saturating
permeabilization with ice-cold methanol. Intracellular Syk phosphorylation was detected upon staining








































FIGURE 4 | Specific cellular binding of vNARs to cell line SUP-B8. Two generated vNAR-Fc variants were an
105 cells were incubated with biotinylated vNAR-Fc molecules followed by incubation with streptavidin-APC. B
CFSE-labeled SUP-B8 cells were mixed with B cells (ratio 1:1) isolated from healthy donors and treated with
streptavidin-APC. Black: only secondary reagent; green: unrelated anti-matuzumab vNAR-Fc; blue: vNAR-Fc
100-nM concentration. After incubation for 5 min at 37°C, cells were fixed with paraformaldehyde followed by
with an anti-phospho Syk antibody (Cell Signaling Technology). Significant differences (p ≤ 0.05) between anti
depicted by * (C). Results are shown as mean ± SD and are representative of three independent experiments
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FIGURE 5 | Induction of cytotoxicity in SUP-B8 cells by vNAR-based antibody-drug conjugates. A genetically engineered Fc fragment was MMAE-modified by using a
sortase to generate vNAR-based antibody-drug conjugates. PABA: p-aminobenzoic acid (A). On-target SUP-B8 as well as off-target Daudi and IM-9 wells were exposed
to varying concentrations of two different MMAE-conjugated vNAR-Fc antibodies (B, C). Fc-mediated cytotoxicity was assessed upon cell treatment with MMAE-modified
solitary Fc fragment (D) and unrelated MMAE-conjugated anti-matuzumab vNAR-Fc (isotype control) (E). vNAR-mediated cytotoxicity was measured based of cell
proliferation after 72 h of antibody treatment. Results are shown as mean ± SEM and are representative of three independent experiments. Significant differences (p ≤
0.05) between on-target and control Daudi and IM-9 cells were determined using a two-way ANOVA test (Bonferroni t-test) and are depicted by * and #, respectively.
Mediation of apoptosis and necrosis was investigated upon treatment of 3 × 105 cells with a 500-nM concentration of vNAR-ADCs. After 24 h of incubation, cells were
stained with Annexin V and propidium iodide (PI) following manufacturer’s protocol (Rottitest® Annexin V, Carl Roth) and analyzed by FACS (F).
Macarró n Palacios et al. Specific Targeting of Lymphoma Cellsused. First, immunoglobulin variable fragments of lymphoma
cell lines were cloned, followed by reformatting and subsequent
expression of recombinant idiotype proteins. A possible
alternative to this procedure would have been the generation of
hybridoma cell lines enabling the secretion of soluble BCR (24)
which would have been a far more time-consuming process.
Furthermore, sequence analysis revealed for BCRs of cell lines
Daudi and IM-9 comprising a kappa light chain whereas cell line
SUP-B8 showed the sequence pattern of a lambda light chain.
Consequently, the VL domains were cloned on the respective
constant domains to prevent the generation of molecules lacking
stability (47). Cloning into expression vectors enabled the
production as full-length IgG bearing an IgG1 Fc and the
subsequent purification via protein A columns. BCRs of SUP-
B8 and IM-9 showed the expected band patterns with heavy and
light chains with correct sizes. However, analyzing Daudi BCRs
revealed a light chain with a smearing band corresponding to the
light chain with a higher apparent molecular size than expected.
This might be caused by the presence of two motifs (N-X-S/T)
for glycosylation sites in the CDR loops of Daudi VL (48). In
general, BCR CDR loops frequently acquire sequence motifs
upon somatic mutation that serve as sites for N-glycosylation e.g.
in follicular lymphoma (49).
Previous studies have shown the potential of vNARs to
interact with the paratope of monoclonal antibodies in an anti-
idiotypic manner (33). This might be caused by anti-idiotypic
vNARs being structurally capable of engaging interspaces at the
interaction site of heavy and light chains of a monoclonal
antibody, which could be attributed to their elongated CDR3
binding sites (27). After FACS-based yeast surface display
screening of the semi-synthetic vNAR-library, the resulting
population of binders still showed a high diversity which
enabled to select the most promising variants. Although no
counter-screen using unrelated antibodies was implemented, it
could be shown that the majority of binders specifically recognize
the antigen in an idiotypic manner. Furthermore, it has to be
mentioned that all binders resulting from this study mainly bind
via amino acid residues in the CDR3. Eight vNAR variants were
reformatted via fusion to a human Fc. Of these, five were able to
be expressed at reasonable yields (50–100 mg/L). Depending on
CDR sequences, it is a well-known problem of many single-chain
antibodies to show low expression yields (50, 51). Evaluation of
vNAR affinities was performed by application of biolayer
interferometry revealing binding constants in the single-digit
nanomolar range. Specificity was assessed again with soluble
protein which resulted for three variants (S2, S4 and S9) in highly
specific binding to the BCR of cell line SUP-B8. This was alsoFrontiers in Immunology | www.frontiersin.org 11true for binding to BCR presenting SUP-B8 cells clearly showing
a specific cellular binding. This also indicated the recombinantly
expressed BCR being folded similarly as the wildtype membrane-
anchored BCR. The combinatorial diversity of the naïve antibody
repertoire in humans is estimated to be at least 1012 unique BCRs
(52). The immense plethora of different idiotypes within an
individual could diminish binding thus limiting the effectiveness
of the antibodies. In this study, vNAR-Fc fusion proteins were
ultimately demonstrated to specifically engage the idiotype of a
malignant cell population being able to distinguish from BCRs
expressed by healthy B cells.
Receptor-mediated endocytosis plays an important role in cell
death induction. BCR clustering and thus triggering of cell
apoptosis might be impaired by rapid antibody internalization,
while efficacy of antibody-drug conjugates is to a large extent
driven by receptor-mediated antibody endocytosis followed by
release of the toxic compound finally causing cell death (53).
Treatment of lymphoma B cells with vNAR-Fc fusion molecules
revealed BCR signal transduction as well as extensive
internalization upon binding of the specific BCR. As expected,
control lymphoma cell lines Daudi and IM-9 bearing different
idiotypes showed significantly lower antibody internalization
levels, likely due to Fc/Fcg receptor interactions rather than
upon unspecific vNAR-mediated BCR engagement. Torchia
et al. have reported anti-idiotype peptibodies bearing four
binding valences to kill lymphoma cells in vitro with specificity
via induction of cell apoptosis by clustering the surface BCRs
(23). Consequently, we investigated our most promising vNAR-
Fc variants S2 and S9 towards their potential cell killing effect on
SUP-B8 cells. This resulted in no observable cytotoxicity even at
higher triple-digit nanomolar concentrations. The lack of vNAR-
Fc-triggered BCR clustering is concordant with different reports
describing that constructs with only two binding valences show
significantly reduced receptor clustering (54). Moreover, neither
addition of an anti-human Fc antibody to SUP-B8-bound
vNAR-Fc nor application of a tetravalent construct with two
additional C-terminally fused vNAR domains lead to a
significant induction of apoptosis (data not shown). It is
tempting to speculate that these observations are mainly
reasoned through rapid internalization and degradation of
vNAR-Fc/BCR complexes triggered by either BCR cross-
linking or interaction of Fc region of vNAR constructs with
the Fcg receptors expressed on lymphoma B-cells (55).
Upcoming studies may reveal whether this issue can be
circumvented by cloning the genes coding for BCR-binding
vNARs into higher multivalent antibody formats. In the case of
VHHs, Drabak et al. reported that it is feasible to generateNovember 2020 | Volume 11 | Article 560244
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domains N-terminally fused to the constant domain or located at
both termini of the Fc portion (56). Furthermore, it would be
possible to use one of the several published scaffolds that enable
multivalent conjugation of proteins e.g. verotoxin B (57, 58) or
the C4-binding protein (59). Previous studies have shown that B
cell activation is triggered by BCR-antigen engagement (60).
Forthcoming studies might reveal more details regarding BCR
activation and eventually internalization upon engagement of
anti-idiotypic antibodies.
Next, we investigated the potential of the vNAR-Fc molecules
to specifically mediate ADCC and ADCP against lymphoma B-
cells. Unexpectedly, experiments revealed no activity to activate
human PBMCs and macrophages for ADCC/ADCP. It is known
that Fc glycosylation plays a critical role in binding to human Fc
receptors and consequently in triggering ADCC or ADCP.
Improper glycosylation patterns present on the vNAR-Fc
antibodies might explain the inefficacy of the Fc fragment to
induce antibody-mediated cytotoxicity/phagocytosis against
malignant B-cells. In addition, a variety of target antigen
characteristics, such as epitope location, antigen density or
molecule design have been described to critically impact Fc-
mediated effector functions. We did not further investigate these
parameters within the scope of this work.
Besides triggering apoptosis by BCR clustering and
engagement of effector cells, it is feasible to investigate the
killing effect of an antibody-drug conjugate. Here, we report a
patient-tailored approach in a proof of concept study based on
the generation of vNAR antibody-drug conjugates that kill
lymphoma B-cells upon specific vNAR-mediated targeting of
the BCR. Enzymatic MMAE-modification of the SUP-B8 BCR-
binding vNAR-Fc candidates S2 and S9 resulted in specific
induction of cytotoxicity in on-target lymphoma B cells at
picomolar concentrations. In contrast, the vNAR-ADCs
showed no significant cytotoxic effect in unrelated CHO cells
as well as off-target B cells in the same picomolar range. Of
note, increasing ADC concentrations led to killing of off-target
lymphoma B cells. Nonspecific cell death caused by lymphoma
B-cell targeting antibody-drug conjugates has been observed in
similar studies (61). As discussed before, this effect might be
derived from antibody/antigen complex uptake and
internalization via interaction with Fcg receptors present on
B cells. Experiments including vNAR-unrelated constructs as
isotype control as well as solitary MMAE-modified Fc
molecules support our hypothesis of Fc/Fcg receptor
interactions being responsible for unspecific cell killing
induced in off-target Daudi and IM-9 cells. Furthermore,
similar cell surface BCR expression levels were observed for
all three lymphoma cell lines. Interestingly, we noticed that
SUP-B8 cells respond more sensitive to both isotype control
and MMAE-conjugated Fc domain. This might be explained by
a higher surface Fcg receptor density compared to Daudi and
IM-9 cells, by an increased antibody/receptor complex
internalization rate or by a different intracellular processing
after antibody-toxin uptake. Despite inducing a nonspecific
cytotoxic effect, the Fc region is responsible for improvedFrontiers in Immunology | www.frontiersin.org 12stability and pharmacokinetics and may promote cell
apoptosis by BCR clustering in toxin-free multivalent
antibody formats.
ADCs for treatment of B-cell non-Hodgkin’s lymphoma and
follicular or diffuse large B-cell lymphoma developed by
Genentech/Roche are being investigated in actual Phase I and
Phase II clinical trials (11). Currently, patients with B-cell
lymphomas such as Burkitt lymphoma and several other Non-
Hodgkin lymphoma types are treated with a combination of
extensive chemotherapy with Rituximab that binds selectively
the B-lymphocyte antigen CD20. Although this therapy has
shown to be very effective, especially utilizing Rituximab for
treatment has several potential disadvantages. On the one hand
Rituximab opsonizes all cells that express the tumor-associated
antigen CD20. The resulting suppression of the whole immune
system increases the risk of infections and viral reactivation (12).
On the other hand it also removes a large population of antigen-
presenting cells (APCs) important for initiation of T-cell-
mediated cellular immunity (62). Further risks are associated
with loss of CD20 expression or the development of lymphoma
cells showing mutated CD20 protein on their surface. As a
consequence, cancer cells are not able anymore to be targeted
by Rituximab (63, 64). Thus, incomplete depletion of malignant
B cells often results in disease relapse and treatment resistance in
patients (65).
Due to their remarkably attributes, harnessing heavy-chain
only antibodies from the adaptive immune system of
cartilaginous fish seems to be a promising approach for the
development of novel therapeutic molecules. Given the
substantial evolutionary distance of cartilaginous fish to
human, however, potential immunogenicity should be taken
into consideration. Yet, previous studies have demonstrated
the feasibility of humanizing vNAR domains in order to
prevent xeno-reactivity (66).
In summary, considering the BCR as tumor-specific cell
surface marker which is also distinct from the BCRs displayed
on non-malignant B cells, we developed a novel strategy for a
custom-tailored targeted therapy to induce death in lymphoma B
cells in a time efficient and inexpensive manner. The herein
demonstrated versatile approach enables the generation of vNAR
antibody drug conjugates against patient-specific lymphoma
cells in a time of less than six months from time point of
starting with material of lymphoma patients. The high
specificity of our vNAR antibodies offers a therapeutic window
enabling the eradication of lymphoma B cells without inducing
overall immunosuppression derived from the ablation of the
whole B-cell subset in patients. Future experiments may enable
the generation of vNAR-Fc antibody formats with higher
binding valences that allow for apoptosis induction of
lymphoma B cells by BCR clustering.CONCLUDING REMARKS
Several therapies based on monoclonal antibodies as well as
small molecules against malignant B cells have been developedNovember 2020 | Volume 11 | Article 560244
Macarró n Palacios et al. Specific Targeting of Lymphoma Cellsduring the last years. These treatments, however, target B cells in
a non-specific manner, thus leading to immunosuppression and
finally to severe side effects (12). The use of antibody-drug
conjugates based on anti-idiotypic vNARs specifically targeting
the BCR might represent a beneficial strategy to induce killing in
lymphoma B cells. The versatile approach described here as an in
vitro proof of concept may overcome technical hurdles derived
from the development of a patient-tailored treatment against
lymphoma-related malignancies.DATA AVAILABILITY STATEMENT
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